Grove Bank & Trust’s Pfizer PFE Stock Holding History

Grove Bank & Trust’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$325K	Sell	13,502 -4,003	-23%	-$105K	0.03%	212
2026 Q1	$492K	Hold	17,505	–	–	0.06%	169
2025 Q4	$436K	Sell	17,505 -4,966	-22%	-$125K	0.05%	179
2025 Q3	$573K	Sell	22,471 -2,352	-9%	-$58.1K	0.07%	154
2025 Q2	$602K	Sell	24,823 -1,708	-6%	-$39.8K	0.08%	154
2025 Q1	$672K	Buy	26,531 +1,554	+6%	+$40.7K	0.09%	139
2024 Q4	$663K	Buy	24,977 +230	+0.9%	+$6.24K	0.09%	134
2024 Q3	$716K	Sell	24,747 -3,028	-11%	-$88.3K	0.11%	126
2024 Q2	$777K	Sell	27,775 -3,814	-12%	-$105K	0.12%	105
2024 Q1	$877K	Sell	31,589 -18,999	-38%	-$527K	0.15%	94
2023 Q4	$1.46M	Sell	50,588 -4,617	-8%	-$140K	0.27%	71
2023 Q3	$1.83M	Buy	55,205 +3,580	+7%	+$127K	0.37%	54
2023 Q2	$1.89M	Buy	51,625 +1,806	+4%	+$70.3K	0.38%	54
2023 Q1	$2.03M	Buy	49,819 +3,032	+6%	+$131K	0.43%	49
2022 Q4	$2.4M	Sell	46,787 -4,652	-9%	-$223K	0.53%	39
2022 Q3	$2.25M	Sell	51,439 -1,270	-2%	-$61.7K	0.56%	40
2022 Q2	$2.76M	Sell	52,709 -2,657	-5%	-$135K	0.66%	35
2022 Q1	$2.87M	Sell	55,366 -1,400	-2%	-$72.6K	0.56%	43
2021 Q4	$3.35M	Buy	56,766 +82	+0.1%	+$4.06K	0.64%	38
2021 Q3	$2.44M	Buy	56,684 +3,142	+6%	+$139K	0.51%	44
2021 Q2	$2.1M	Buy	53,542 +2,126	+4%	+$82.7K	0.45%	50
2021 Q1	$1.86M	Sell	51,416 -1,097	-2%	-$39K	0.44%	54
2020 Q4	$1.93M	Buy	52,513 +1,528	+3%	+$56K	0.5%	49
2020 Q3	$1.77M	Sell	50,985 -2,885	-5%	-$101K	0.54%	45
2020 Q2	$1.67M	Buy	53,870 +6,505	+14%	+$221K	0.55%	47
2020 Q1	$1.47M	Buy	47,365 +4,496	+10%	+$153K	0.58%	44
2019 Q4	$1.59M	Buy	42,869 +1,535	+4%	+$54.7K	0.48%	51
2019 Q3	$1.41M	Buy	41,334 +5,741	+16%	+$209K	0.45%	52
2019 Q2	$1.46M	Buy	35,593 +90	+0.3%	+$3.57K	0.53%	44
2019 Q1	$1.43M	Buy	35,503 +2,185	+7%	+$87.5K	0.55%	43
2018 Q4	$1.38M	Buy	33,318 +3,162	+10%	+$131K	0.64%	38
2018 Q3	$1.26M	Sell	30,156 -87	-0.3%	-$3.35K	0.52%	51
2018 Q2	$1.04M	Sell	30,243 -960	-3%	-$32.8K	0.44%	61
2018 Q1	$1.05M	Buy	31,203 +232	+0.7%	+$7.98K	0.47%	56
2017 Q4	$1.06M	Buy	30,971 +134	+0.4%	+$4.57K	0.46%	56
2017 Q3	$1.04M	Buy	30,837 +7,368	+31%	+$237K	0.51%	50
2017 Q2	$748K	Buy	23,469 +13,340	+132%	+$421K	0.48%	53
2017 Q1	$329K	Buy	10,129 +2,311	+30%	+$72.9K	0.27%	72
2016 Q4	$241K	Buy	7,818 +5,566	+247%	+$170K	0.18%	94
2016 Q3	$73K	Hold	2,252	–	–	0.06%	134
2016 Q2	$75K	Buy	2,252 +1,623	+258%	+$51.8K	0.07%	134
2016 Q1	$18K	Buy	629 +105	+20%	+$3K	0.02%	201
2015 Q4	$16K	Buy	+524	New	+$16.5K	0.01%	249

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Grove Bank & Trust's PFE Position: Q2 2026 in Review

Grove Bank & Trust reduced its Pfizer (PFE) stake by 23% in Q2 2026, selling an estimated $105K and leaving 13,502 shares worth $325K. The position accounts for 0.03% of the portfolio, ranked #212.

Grove Bank & Trust first reported a position in PFE in Q4 2015 and has held it in 43 quarters since. The position peaked at $3.35M in Q4 2021. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Grove Bank & Trust held 13,502 shares of Pfizer worth $325K as of Q2 2026.
Grove Bank & Trust sold 4,003 Pfizer shares in Q2 2026, an estimated $105K.
Pfizer made up 0.03% of Grove Bank & Trust's portfolio in Q2 2026, its #212 holding.
Grove Bank & Trust first reported a position in Pfizer in Q4 2015 and has held it in 43 quarters since.
Grove Bank & Trust's Pfizer position peaked at $3.35M in Q4 2021.
2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.